Dr. Kai Hu, Hematologist - Beijing, China

Dr. Kai Hu - Hematologist/Lymphoma, Multiple Myeloma

About Dr. Kai Hu

Dr. HU is the Chief Physician and Director in Lymphoma and Myeloma Department at Beijing Gobroad Hospital and he is Doctor of Medicine.

Educational Background:

Dr. HU graduated from West China University of Medical Sciences with a bachelor's degree and obtained a doctorate in internal medicine and hematology from Peking University Health Science Center in 2012. He worked at Peking University Third Hospital from 2005 to 2019 and has been with Beijing Gobroad Hospital since 2019.

Professional Expertise:

Currently he is engaged in multidisciplinary comprehensive treatment of hematological malignancies, specializing in the early diagnosis of lymphoma, multiple myeloma, and leukemia, comprehensive standardized treatment mainly based on internal medicine chemotherapy, molecular targeted therapy, autologous/allogeneic hematopoietic stem cell transplantation, and biological therapy. Conducts in-depth research on immunotherapy guided by biomarkers and is well-versed in the latest international diagnostic and treatment standards for lymphoma. Participated in over 20 international and domestic multicenter clinical studies, keeping up with the latest advancements in the diagnosis and treatment of lymphoma and multiple myeloma. First author and corresponding author of more than 30 Chinese and English papers, and has co-edited and co-translated 5 books.

Research Achievements:

1. Utility Model Patent, Invention Name: A Separation Device, Patent Number: 201420394032X

2. EHA Oral Presentation:

l  Genetic landscapes and curative effect of CAR T-cell immunotherapy in relapse and refractory DLBCL patients.

3. ASH Oral Presentation:

l  Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma.

l Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Failure of Murinized CD19 CAR-T Therapy.

Science Popularization and Interaction:

l  Member of the Elderly Oncology Committee of the Chinese Society of Geriatrics

l  Member of the Health Science Popularization Committee of the Chinese Health Management Association

l  Member of the Hematopoietic Stem Cell Transplantation and Cell Therapy Committee of the Chinese Medical Education Association

l  Member of the Clinical Research Committee of the Beijing Tumor Association.

l  Youth Committee Member of the Hematology Committee of the Beijing Medical Association